Making the international connection – a global view on research spending trends

Posted on Feb 24th, 2015 - By nicolaharris - 0 Comments

NCRI plays a pivotal role in fostering collaboration across cancer research in the UK – providing a forum to share information, expertise and ideas to ensure we are tackling important research questions effectively and efficiently and that, ultimately, progress against cancer is being made faster. But what about international collaboration? Here, Dr Kieran Breen, our Head of Programmes and Evaluation tells us about one of the ways NCRI helps to extend this forum internationally – to help us gain a global view on research spending trends.

Here in the UK, NCRI collects information annually on the research funded by our 21 cancer research funding Partners. This is held in our cancer research database (CaRD) which is a unique resource that we use to analyse research spending trends – highlighting areas of relative research strength as well as areas which may require more investment. This helps the NCRI identify areas that may benefit from collaborative working.

This information is available to all Partners as well as to external researchers upon request. We also make top-level findings publicly available on our website.

» Further information on CaRD (NCRI webpage)

The International Cancer Research Partnership
NCRI is the UK member of the International Cancer Research Partnership (ICRP) – an alliance of cancer research funding organisations from the USA, Canada, Australia, France, Japan, the Netherlands and UK) working together to improve access to information about cancer research internationally.  And it is through this partnership that the NCRI are able to connect the data from our Partners in the UK with international funding data, helping to build a picture of global research spending trends.

» Further information on ICRP (external webpage)

Connecting the data
Every year, NCRI submits details of the research funded by our Partners to ICRP and this is uploaded into the combined database. This combined database contains information on over 60,000 research grants, totalling over $15bn – representing a large portion of the cancer research performed in North America, Europe, Japan and Australia and this represents a significant proportion of worldwide cancer research funding outside the industrial sector.

Getting a global view on research spending trends
ICRP analyses the cancer research funding and publishes periodic reports on a variety of topics; from detailed analysis enabling comparison of research spending patterns between the UK and other countries, to more specific reports that examine trends in research investment.

» ICRP publications (external webpage)

ICRP members also have access to the detailed data and can use this to assess changes in funding patterns over time as well as comparing funding priorities internationally. For instance, we recently analysed the ICRP database to look at the nature and volume of childhood cancer research funded by NCRI Partners in the UK compared with other countries. This was in response to a request by the UK children’s cancer community to benchmark UK activity against work elsewhere.

» NCRI childhood cancer report, 2014 (PDF)

ICRP also make their database available to the public, so researchers, funders and others can see what is going on internationally.

» The ICRP public database (external webpage)

Further information

» Email the NCRI database team

Continue Reading

Clinical study concept registration scheme

Posted on Jun 3rd, 2015 - By nicolaharris - 0 Comments

Clinical study concept registration scheme

An NCRI scheme to register and initiate collaborative discussions of clinical study concepts has recently been launched.

The NCRI Study Concept Registration scheme will provide a route for researchers to initiate collaborative discussions with members of relevant NCRI Clinical Studies Groups (CSGs) about their new or developing clinical study concept. When a study is submitted, the NCRI Executive will ‘match-make’ between CSGs and Advisory Groups to facilitate collaborative discussions and provide expert advice. In addition, the scheme will enable the NCRI Executive to keep a clear record of study concepts and their progress.

Researchers may submit any clinical study, including  trials or observational studies, which are being developed by the CSG or CSG Subgroups or studies where a new translational or add-on component is proposed for an existing study – this may also include studies submitted by researchers outside the CSGs. Typically studies will be submitted just before or after the funding application stage – so that discussions are focused on development and optimisation of  proposals.

» Further information about the NCRI Study Concept Registration scheme (CSG webpage)


Continue Reading

Hitting the ground running – news from the NCRI Consumer Forum

Posted on Jul 14th, 2015 - By nicolaharris - 0 Comments

Hitting the ground running – news from the NCRI Consumer Forum

The new NCRI Consumer Forum has been formed to take over the role of the former Consumer Liaison Group (CLG), with a more focussed remit. The Forum is chaired by Richard Stephens in his new role as Interim NCRI Consumer Lead.

The forum aims to foster a vibrant and collaborative community to work with NCRI as partners in cancer research; exchanging knowledge and expertise in a coordinated way. Further information on the forum, including its remit and membership can be found at the link below.

» Further information about the NCRI Consumer Forum (internal webpage)

The NCRI Consumer Forum had a strong presence at the NCIN Conference in Belfast in June.  17 members attended, two of them hosting Plenary Sessions, and several asking questions from the floor and contributing to debates. Helen Bulbeck and Margaret Grayson were award-winners for poster presentations as co-authors with researchers, whilst Carolyn Morris, Mat Baker and others produced a triptych of posters about the National Cancer Patient Experience Survey.

The three posters show responses to  survey questions about awareness of research, and the leading poster, “Keeping the Customer Satisfied #1” won two awards, one from the Conference Committee and also one of the Patient Choice Awards voted for at the conference itself.

Poster success -2015 NCIN Conference

Proud of the Forum’s success: Richard Stephens, NCRI Consumer Lead and Karen Kennedy, NCRI Director at the “Keeping the Customer Satisfied #1” poster, 2015 NCIN Conference.

“The [Keeping the Customer Satisfied #1] poster shows that patients who participate in research, or even who just have a conversation about research, are more likely to report satisfaction with their care,“  Richard Stephens explains. “ It is very pleasing that its significance was recognised both by researchers and clinicians and also by the patients and public who were at the conference. The poster’s findings are a powerful message to take into the NIHR networks and the devolved nations.”

All three posters on the National Cancer Patient Experience Survey can be viewed at the links below.

» Keeping The Customer Satisfied #1: Is Taking Part in Research Associated With Better Experience of Care? Findings from the 2013 National Cancer Patient Experience Survey (PDF, 2013)

» Keeping The Customer Satisfied #2 It Is OK To Ask – Who Are We Asking, And Who Participates? Further Findings from the National Cancer Patient Experience Survey 2013 (PDF,2013)

» Keeping The Customer Satisfied #3: It Is OK To Ask – Who Are We Asking? Variations by Type of Cancer Findings from the 2013 National Cancer Patient Experience Survey (external website poster abstract: Day 2, poster number P-124)


Continue Reading

CTRad: developing the latest radiotherapy trials

Posted on Jul 14th, 2015 - By nicolaharris - 0 Comments

CTRad: developing the latest radiotherapy trials

CTRad logo

CTRad organises Proposal Guidance Meetings up to twice a year, where investigators who have ideas for radiotherapy research are invited to present their proposals for open discussion and feedback from a panel of CTRad experts. The most recent meeting took place in June and, aswell as being a milestone as the tenth meeting, it was also the first meeting where ideas in proton beam therapy (PBT) research were brought to the table.

13 radiotherapy proposals ideas were discussed at the half-day meeting; including multiple ideas for research in radiotherapy for lung cancer and also multiple ideas in PBT.

Professor Neil Burnet, Chair of CTRad said, “The proposals guidance meetings are always a great way for investigators to bounce ideas around with other experts and gain valuable insights into ways they can further develop their radiotherapy research proposals. They also open up opportunities for networking and collaboration.”

“In this meeting we were especially delighted to see four early ideas in PBT being discussed – this is the first time that ideas around research using PBT have been brought to CTRad and it reflects the growing interest in this area in anticipation of the first PBT centres that will be opening in the UK over the next few years. It’s also a credit to the work that CTRad are doing in starting national conversations about how we’ll develop high-quality research using PBT once the UK centres are open.”

A call for research proposals to be discussed at the next proposals guidance meeting will be announced soon, along with further details of this next meeting.

» Further information on CTRad proposals guidance meetings (CTRad webpage)

In the meantime, if you are an investigator working on a radiotherapy-themed clinical research proposal you can approach CTRad’s Radiotherapy Clinical Trials Advisory Service (RADCAS) team for specialist advice.

» Further information on RADCAS (CTRad webpage)


Continue Reading

Looking for a single efficient way of exploring EORTC collaboration? The EORTC Collaboration Pathway has now been launched

Posted on Jul 16th, 2015 - By nicolaharris - 0 Comments

Looking for a single efficient way of exploring  EORTC collaboration?  The EORTC Collaboration Pathway has now been launched

The European Organisation for Research and Treatment of Cancer (EORTC) provides a pan-European network of experts and the infrastructure for carrying out translational and clinical  cancer research across Europe. Members of our NCRI Clinical Studies Groups (CSGs) have been collaborating with the EORTC  when necessary, however the connections have primarily been via personal links and a consensus on a single efficient mechanism to explore EORTC clinical trial collaboration has been lacking – until now.

The UK EORTC Liaison Officer, at Cancer Research UK (CRUK), has developed a pathway to highlight the key steps involved in exploring EORTC collaboration when developing a clinical trial (for both UK- and EORTC- initiated studies). These pathways are available to download from both the NCRI CSG website and the EORTC website.

» Collaboration pathways for exploring EORTC collaboration (NCRI CSG webpage)

Alongside the pathways a confidentiality framework has been developed to protect against the sharing of study information outside of the collaboration discussions.  This framework forms the basis of a ‘conditions of use’ agreement associated with utilising the Collaboration Pathways the details of which are sent on a study-by-study basis.

Further information

» Find out more about the EORTC (EORTC website)

» Contact the UK EORTC Liaison Officer at CRUK (email)


Continue Reading

NCRI Clinical Studies Groups: latest Chair rotations

Posted on Aug 21st, 2015 - By nicolaharris - 0 Comments

NCRI Clinical Studies Groups: latest Chair rotations

Chairs for the CSGs rotate every three years with an option to reapply for a further three years. Recruitment rounds usually run in summer, where vacancies are available. The next round of recruitment will be in summer 2016.

See below for announcements of the latest incoming and outgoing Chairs.

Chair rotations:

  • NCRI Renal CSG: Dr Paul Nathan (incoming), Dr James Larkin (outgoing)
  • NCRI Testis CSG: Dr Jonathan Shamash (incoming),  Professor Johnathan Joffe (outgoing)
  • NCRI Bladder CSG: Dr Alison Birtle has been reappointed for a second term
  • NCRI Head & Neck CSG: Professor Hisham Mehanna has been reappointed for a second term

A full list of CSG Chairs and members can be found on the CSG website.

» NCRI CSG Groups list (CSG webpage)

Continue Reading

Update from the Combinations Alliance

Posted on Sep 10th, 2015 - By nicolaharris - 0 Comments

Update from the Combinations Alliance

Hazel Jones, Cancer Research UK’s Head of Combination Therapies, talks to us about the latest collaborations and opportunities to get involved and explore the use of new therapies in combination strategies.

Combination strategies must be investigated earlier in the drug development pipeline to maximise treatment opportunities for people with cancer. Even with their significant resources, drug companies can only explore a fraction of all possible combinations.

Launched in 2010, the Combinations Alliance is supported and governed by Cancer Research UK’s (CRUK) Centre for Drug Development (CDD) and offers a collaborative model. For academic researchers, this offers the opportunity to increase the number of novel combination treatment options and for industry, this provides the opportunity to broaden potential markets for their novel drugs. The Combinations Alliance is also driving cross-company collaborations, to establish a position as broker, hence progressing the most promising combinations.

Current collaborations

The Combinations Alliance now has nine industry partners including recent collaborations with Biothera, Plexxikon, Clovis, Verastem and Immudulon and the longstanding commercial partnerships with AstraZeneca, MedImmune, Lilly and Astex. The partners offer one or more novel drugs for academics to explore different combinations of therapies, including radiotherapy, in early phase clinical trials. Active discussions are ongoing with several other companies and researchers are encouraged to complete our ‘Drugs of Interest’ survey on our website.

» Drugs of interest survey (external webpage)

With a growing and transitioning portfolio, success has now been demonstrated both with delivery of trials and the opportunities they can offer, such as expansion into wider disease areas shown by TAX-TORC demonstrating efficacy in ovarian and squamous cell lung cancer. Furthermore, novel intra-patient dose escalation in CompAKT and delivering the first trial in neuroendocrine tumours in VIBRANT, shows the varied nature of our work.

Opportunities to get involved

There are ongoing opportunities to get involved and maximise the effective use of new therapies in combination with other novel agents, immunotherapy or conventional chemotherapy or radiotherapy.

In order for a novel combination to progress to an early phase clinical trial, preclinical evidence is required to support the idea. CRUK’s preclinical combination scheme can provide the funding to support these types of combination study. Furthermore, the Radiotherapy-drug combinations consortium (RaDCom), established by NCRI’s Clinical and Translational Radiotherapy research working group (CTRad) and CRUK, can help investigators develop ideas and deliver supporting preclinical evidence for novel radiotherapy-drug combinations.

» Funding for preclinical studies of new drug combinations (CRUK webpage)

Calls for novel clinical combination ideas are made to the ECMC network and planned three times per year. The next call is planned for early December. In advance of the call we are holding a workshop on  Wednesday 4 November at this year’s NCRI Cancer Conference in Liverpool.

» Workshop at the NCRI Cancer Conference (internal webpage)

Further information

» Combinations Alliance webpage

» Email the Combinations Alliance


Continue Reading

Ximbio: a new way to exchange knowledge and trade research reagents from Cancer Research Technology

Posted on Sep 17th, 2015 - By nicolaharris - 0 Comments

Ximbio: a new way to exchange knowledge and trade research reagents from Cancer Research Technology


Ximbio is a website for the life science community to exchange knowledge and trade research reagents such as mouse models, antibodies, cell lines and small molecules. Launched last year, it originates from Cancer Research Technology, the development and commercialisation arm of Cancer Research UK. Ximbio aims to unify the life science community to make research tools widely available and accelerate research. Researchers and Technology Transfer Offices can virtually upload their reagents to the Ximbio website, making them globally visible. For scientists looking for a specific reagent, Ximbio offers a fully searchable database, extensive datasheets, peer reviews and supplier options for over 1000 products.

» Find out more (Ximbio website)

Continue Reading

Latest news from the NCRI Consumer Forum

Posted on Nov 23rd, 2015 - By nicolaharris - 0 Comments

NCRI Consumer Forum members had a busy 2015 NCRI Cancer Conference. A poster on show, the highly esteemed Dragon’s Den and a 50 hour ‘hackathon’.

Poster: the Forum’s latest analysis of the National Cancer Patient Experience Survey

The Forum’s latest analysis of the 2014 National Cancer Patient Experience Survey (NCPES) data looked at the association between age and access to research opportunities. They found that there has been little change nationally from 2013 and that older patients are still not asked to take part in research as often as younger patients. Lead author of the research Carolyn Morris presented the research to delegates during the poster session at the Conference. She said “These findings show inequality of access to research opportunities for cancer patients. And they show that overall things aren’t changing….It is in everyone’s interest to have more research opportunities in our cancer services, for those opportunities to be offered to cancer patients, and for patients, advocates and charities to ask for them.”

» View the poster presented at the 2015 NCRI Cancer Conference (PDF, 2015)

The NCRI Consumer Forum Dragon’s Den – including a ‘hackathon’

The NCRI Consumer Forum’s Dragon’s Den is an opportunity for researchers to put their study proposals to a panel of consumers and gain the benefit of their unique perspectives and experiences. This year the event was sponsored by Cancer Research UK – and it was even bigger than previous years, with nine research teams attending to meet with nearly 100 consumers. The research ideas discussed ranged from early phase pharmaceutical studies, later phase radiotherapy trials, and even the launch of a 50-hour ‘hackathon’ with AstraZeneca, looking at designing a mobile application for trial participants.

“This year was more crowded than in the past,” said NCRI Consumer Forum Chair, Richard Stephens, “But also more purposeful. We had a little more time and many of the consumers and some of the researchers have done it before.”

“We were pleased to come back to the Dragon’s Den,” added Jenny Royle, an AstraZeneca researcher, “And we are learning to harness consumer involvement for a variety of reasons – a couple of clinical studies, our ‘hackathon’ and a very useful discussion on certain types of side effects and how patients and carers view the balance between severity and frequency.”

“It was good too to link the Dragon’s Den event more closely with other Conference activities,” Richard added, “We supported CTRad researchers preparing for their Wednesday workshop and we helped NIHR with a proposal that links to their Patient Research Ambassador programme, which was the topic of other work later on at the Conference. And on Wednesday morning, we had another session with AstraZeneca to conclude their 50-hour global ‘hackathon’, which was not only very enjoyable for us, but helps us to encourage pharmaceutical companies to continue their support for the Conference.”

» Find out more about the NCRI Consumer Forum (NCRI webpage)

» Find out more about NCRI’s CTRad initiative (NCRI webpage)

Continue Reading

NCRI’s top 10 highlights of 2015

Posted on Dec 4th, 2015 - By nicolaharris - 0 Comments

From hosting the UK’s largest cancer research meeting to launching a game changing initiative in pathology, 2015 has been a busy year. NCRI Director Karen Kennedy picks her ‘top 10’ NCRI highlights for 2015.

Karen says, “It was tough to pick just 10 – we run many collaborative activities across a range of specialisms and we work with a diverse group of people; all sharing their expertise and ideas and working collaboratively to help make faster progress in cancer research. It goes without saying that all of the achievements you see below are due to the dedication and collaborative spirit of many, so on behalf of the NCRI Team I’d like to thank all those involved for their continued support of NCRI’s work. Have a great festive season and New Year”.

1. 2015 NCRI Cancer Conference

ABPCO Conference

With over 1700 attendees, 150 speakers and 650 posters presented, the 2015 Conference was a great success. The Conference covered a range of basic, translational and clinical subjects, with a number of sessions exploring broader issues such as E-cigarettes or cancer and physical activity. Over 90% of attendees said they would recommend the Conference to a colleague. There was also a mix of symposia, plenary lectures and networking opportunities – something for everyone. As you can imagine, a Conference of this size and breadth takes a lot of organising, and it is all supported by our in-house NCRI Conference team, who do a brilliant job. This year their achievements have been recognised by the Association of British Professional Conference Organisers (ABPCO) – I’m pleased to congratulate them on their 2015 ABPCO best in-house Conference organiser finalist award (awarded for the 10th NCRI Cancer Conference), which they accepted earlier this month in Brighton (pictured: Deborah and Nicole from the Conference team receiving the award).

» View some of the highlights of the 2015 NCRI Cancer Conference (NCRI webpage)

2. CTRad going strong

CTRad logo

Now in its sixth year, and with a new block of funding agreed until 2018, our radiotherapy initiative, CTRad, is going strong. Its recent activities to boost radiotherapy research include a workshop to scope ideas for Cancer Research UK’s Grand Challenge, a proton beam therapy research town meeting and a research proposals guidance meeting where investigators who have ideas for radiotherapy research are invited to present their proposals for open discussion and feedback from a panel of CTRad experts.

» Find out more about CTRad (NCRI webpage)

3. New Chair and Trustees

Delyth Morgan

In June, we welcomed NCRI’s new trustees and Chair. We have been fortunate enough to have esteemed Chairs of NCRI over the years and our latest is no exception; Baroness Delyth Morgan, Chief Executive of Breast Cancer Now took up the NCRI Chair role, succeeding Dr Harpal Kumar. Baroness Morgan is one of five of our trustees who were elected at NCRI’s Annual Meeting in June. Other Trustees are Dr Helen Campbell (Department of Health), Ms Cathy Gilman (Bloodwise), Ms Shirley Harrison (lay trustee) and Professor Peter Johnson (Cancer Research UK). We plan to further strengthen our board ensuring it is as skilled and diverse as possible. As such we will be advertising for additional trustees to join the Board early in 2016. Further details will be available on our website when the recruitment process kicks off in the new year.

» Find out more about NCRI Chair and Trustees (NCRI webpage)

4. The first NCRI Summer Meeting

NCRI Summer meeting

The 2015 NCRI Summer Meeting, held in June, was an opportunity for NCRI Partners and key stakeholders to come together and review progress made so far in NCRI’s initiatives and to look forward to priorities for NCRI in the year ahead and further potential for collaboration. We had a wealth of expertise and knowledge in the room and we covered a diverse range of NCRI initiatives – our initiatives seek to address the big issues across the research spectrum and patient pathway. I was really impressed with the enthusiasm and support in the room; we all know that it’s so important to work together, across organisations and specialities, if we want to make faster progress against cancer.
» Read a summary of our Summer Meeting (NCRI webpage)

5. Launch of the NCRI Cellular Molecular Pathology (CM-Path) initiative

cm-pathWe’ve known for a while that there are barriers to undertaking pathology research in the UK and NCRI produced a report and recommendations to address these back in 2009, however little improvement has occurred since then. As a result, NCRI together with the ECMC Pathology Network Group consulted with the research community and identified priority areas for action. This was formulated in to a plan for an NCRI initiative and was presented to NCRI Partners at the NCRI Summer Meeting in June 2015. Partners agreed it was an excellent proposal and a subset of them have committed funding for the next five years to support academic cellular molecular pathology in the UK and make the resulting benefits available to the wider research community.
» Find out more about NCRI CM-Path (NCRI webpage)

6. Over 60 CSG meetings and a new interactive map of clinical studies

Interactive portfolio mpas2015 has been another busy year for the NCRI Clinical Studies Groups (CSGs). Across our 20 CSGs we’ve delivered over 60 CSG meetings, bringing together hundreds of clinicians, scientists, statisticians and lay representatives to coordinate the development of a strategic portfolio of cancer clinical trials in the UK. This year also saw the launch of the new interactive portfolio maps. The NCRI CSG portfolio maps provide a visual representation of a CSGs portfolio of studies, highlighting areas of clinical cancer research that are currently well represented, and where there are any gaps. The new version brings all the portfolio maps (previously available as individual PDFs) together in to one interactive platform that can be searched and filtered by criteria such as study phase, funding type and study status. They were developed by NCRI in collaboration with NIHR CRN: Cancer and with a one-off grant from Roche Products Ltd.  The next step for the maps will be the addition of a geo-localisation function, enabling the user to search for studies that are open for recruitment or in set-up phase in a particular area in the UK.
» Find out more about the NCRI Clinical Studies Groups (NCRI webpage)

7. A new NCRI Consumer Forum

Poster success -2015 NCIN ConferenceEarlier this year, as a result of changes within the Networks and the transfer of responsibility for consumer activity to the NCRI, we completed a comprehensive review of consumer involvement across all NCRI activities. A key outcome of the review was the establishment of the NCRI Consumer Forum (it replaces the former Consumer Liaison Group). The NCRI Consumer Forum has been ably led thus far by Richard Stephens in his role as NCRI Consumer Lead and it has been a hive of activity. There was a strong Forum presence at the NCIN conference in Belfast in June (with a number of the Forum’s posters winning prizes – pictured), the Forum also presented posters on patient involvement in research at the NCRI Cancer Conference in Liverpool in November, and ran the highly successful Dragon’s Den session which saw more consumers and researchers in attendance than ever before.

» Find out more about the NCRI Consumer Forum (NCRI webpage)

8. £498m of research funding captured in the NCRI Cancer Research Database


NCRI has been collecting research funding data since 2002,  to understand how money is spread across the various areas of research, and identify trends and gaps in funding across a range of research areas. To track how UK funding changes over time, our Partner organisations are asked to submit data each year on how much they have spent on research, and the research projects and programmes that they spent it on. NCRI publishes annual summaries of the data on our website, as well as periodic reports looking at trends or particular areas within the portfolio. NCRI Partners can also use the information to undertake detailed analyses of their own. This year marked the thirteenth consecutive year of collecting NCRI Partners’ cancer-relevant research funding. The total level of funding came to £498 million (this total has remained around the half billion pound mark since 2009) and once again the three largest areas of research were in biology, early detection, diagnosis and prognosis and treatment. Looking back to 2009, it appears as though the proportion of research into biology is dropping slightly while the opposite is true for the other two areas. Meanwhile the top five cancer sites included breast cancer, leukaemia, colon and rectal cancer, prostate cancer and lung cancer, this has remained the case since 2012 and all five of these research areas saw an increase in funding compared to five years ago.

» Find out more about NCRI’s Cancer Research Database (NCRI webpage)

9. Sharing insights internationally

S ICRP logo stacked white bkgr

NCRI is the UK member of the International Cancer Research Partnership (ICRP) – an alliance of cancer research funding organisations from the USA, Canada, Australia, France, Japan, the Netherlands and UK – working together to improve access to information about cancer research internationally. And through this partnership we are able to connect UK research funding information (collected in the NCRI cancer research database) with international funding data, helping to build a picture of global research spending trends. Earlier this year I attended ICRP’s annual meeting (this year in Canada) where there were opportunities to network and share best practice with other cancer research funding organisations. We heard updates and overviews on various cancer research initiatives across the countries within the ICRP. Whilst in Canada, I was also invited to visit the Canadian Cancer Research Alliance (CCRA) – the Canadian equivalent of NCRI – to share insights in to how NCRI is developing its role to foster collaboration and provide oversight of cancer research in the UK.

» Find out more about NCRI’s international collaboration (NCRI webpage)

10. Future of Surgery workshop series


Research spend in surgery is low, despite surgery being an important aspect of many cancer patient’s journeys. Analysis of the NCRI Cancer Research Database highlighted a low overall volume of surgical research in cancer and this analysis prompted the 2012 NCRI report, Challenges and opportunities in surgical cancer research in the UK. Despite the low volume of cancer surgery studies, UK surgeons have delivered a number of exemplary trials in cancer and there is enthusiasm from surgeons to take on studies and motivate the next generation. The NCRI Future of Surgery workshop series aims to bring the surgical research community together and influence the future of surgery research in cancer by running a series of workshops covering challenging and cross-specialty topics. There will be five workshops running over the next two years in partnership with the Royal College of Surgeons, and workshop leads have been selected to run the workshops, following a competitive open application process. The first workshop “Trials are only as credible as their endpoints”: defining the future outcomes of surgical research, will be held on Wednesday 4 May 2016.

» Find out more about the NCRI Future of Surgery workshop series (NCRI webpage)

Continue Reading